A Phase 3 trial evaluating effect of LB-102 in psychiatric indications
Latest Information Update: 30 Jan 2025
Price :
$35 *
At a glance
- Drugs Amisulpride (Primary)
- Indications Schizophrenia
- Focus Therapeutic Use
- 22 Jan 2025 According to a Segal trials media release, LB Pharmaceuticals plans to engage with the USFDA to finalize this trial's design by early 2026.
- 15 Jan 2025 New trial record
- 08 Jan 2025 According to LB Pharmaceuticals media release, company plans to develop this trial based on topline results from NOVA phase 2 study